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OBJECTIVES We sought to evaluate the incidence of silent ischemia versus symptomatic ischemia six
months after percutaneous coronary intervention (PCI) and its impact on prognosis and to
test the utility of myocardial perfusion single-photon emission computed tomography
(SPECT), or MPS, for risk stratification in these patients.
BACKGROUND Silent ischemia is frequent after PCI. However, little is known about silent ischemia and
long-term outcome after PCI and stenting.
METHODS In 356 consecutive patients with successful PCI and stenting and follow-up MPS after six
months, long-term follow-up (4.1  0.3 years) was performed. The MPS images were
interpreted by defining summed stress, rest, and difference scores (summed difference score
[SDS]  extent of ischemia) and related to symptoms and outcome. Critical events included
cardiac death, myocardial infarction, and target vessel revascularization.
RESULTS Eighty-one patients (23%) had evidence of target vessel ischemia, which was silent in 62%.
The only independent predictor of silent ischemia was SDS (odds ratio 0.64, p  0.001).
During follow-up, 67 critical events occurred. For patients with an SDS of 0, 1–4, and 4,
the critical event rates were 17%, 29%, and 69%, respectively. Similarly, patients without
ischemia, silent ischemia, and symptomatic ischemia had 17%, 32%, and 52% of critical
events, respectively. Diabetes (relative risk 1.98, p  0.03) and SDS (relative risk 1.2, p 
0.001) were independent predictors of critical events. The MPS image added incremental
information for the prediction of critical events.
CONCLUSIONS Six months after PCI and stenting, 23% of patients had target vessel ischemia, which was
silent in 62%. Silent ischemia predicted a worse outcome than did no ischemia and tended to
have a better outcome than symptomatic ischemia. This was closely related to the extent of
ischemia. The SDS added incremental value to pre-scan findings with respect to diagnosis
and prognosis, indicating the utility of MPS for risk stratification after PCI and
stenting. (J Am Coll Cardiol 2003;42:33–40) © 2003 by the American College of
Cardiology Foundation
Restenosis is the main problem in patients who have had a
percutaneous coronary intervention (PCI). Restenosis rates
have been reduced by the frequent use of stents (1,2), from
between 20% and 65% before stenting (1–3) to a level of
15% to 32% (average 20%) with stenting (4,5), depending
See page 41
on the method of follow-up and the criteria used to define
restenosis. It has been reported that 14% to 60% of patients
with restenosis do not complain about recurrent symptoms
(6,7). Still, restenosis has been shown to be prognostically
relevant. This seems to be related to the myocardium at risk
behind the restenotic lesion (6). However, there are almost
no data available on objective measures of ischemia after
PCI and stenting (8) and of its prognostic importance.
Based on its ability to assess and quantify myocardial
ischemia and scar, myocardial perfusion single-photon
emission computed tomography (SPECT), or MPS, has
been shown to provide prognostic information in multiple
coronary artery disease (CAD) settings (9–15).
Therefore, the goals of the present study were fourfold: 1)
to evaluate the incidence of silent ischemia versus symptom-
atic ischemia after PCI and stenting; 2) to identify predic-
tors of silent ischemia versus symptomatic ischemia in these
patients; 3) to define predictors of long-term outcome in
patients with respect to their symptomatic status; and 4) to
determine the incremental value of nuclear testing over
clinical and stress testing variables.
METHODS
Study population. All 369 consecutive patients who un-
derwent successful PCI and stenting at our institution in
1997 and who were followed up after six months by routine
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MPS form the basis of this study. They were prospectively
followed up after a minimum of three years (range 3.2 to 4.9
years; average 4.1  0.3 years). Only 13 patients (3.5%)
were lost to follow-up, leaving a study population of 356
patients (diagnostic patients) (Fig. 1). Seventeen patients in
whom the results of MPS resulted in early revascularization
(PCI or coronary artery bypass grafting [CABG] 60 days
after nuclear testing [16,17]) and 32 patients with evidence
of ischemia in areas other than the target vessel were
excluded from the prognostic analysis of this study, resulting
in a prognostic population of 307 patients (Fig. 1).
Angioplasty and stenting. Angioplasty and stenting were
performed according to published guidelines (18,19). All
patients received heparin to a target activated thrombin time
level of 200 to 300 s, and all patients were taking aspirin
(100 mg/day). In addition, all patients received ticlopidine
or clopidogrel in standard doses for four weeks, as well as
routine statin therapy.
Rest/stress myocardial perfusion protocol. After six
months, all patients underwent a routine rest/ergometry
stress technetium-99m (Tc-99m) sestamibi MPS protocol.
Whenever possible, beta-blockers as well as negative chro-
notropic calcium antagonists were withheld for 48 h and
long-acting nitrates for 24 h before exercise testing. A
rest-SPECT scan was obtained after administration of 400
MBq Tc-99m sestamibi. A symptom-limited exercise test
was performed, using routine protocols with a 12-lead
electrocardiographic (ECG) recording each minute of exer-
cise and 12-lead ECG monitoring throughout the test. End
points of exercise testing were physical exhaustion, severe
angina, sustained ventricular arrhythmia, or exertional hy-
potension. At near-maximal exercise, an 800-MBq dose of
Tc-99m sestamibi was injected, and exercise was continued
for an additional minute after injection. Blood pressure was
measured and recorded at rest, at the end of each stress
stage, and at peak stress. The maximal degree of ST-
segment change at 60 ms after the J point of the ECG was
measured and assessed as horizontal, downsloping, or up-
sloping. The ECG response was categorized as either
nonischemic (no significant ECG changes), ischemic
(1-mm horizontal, downsloping or 1.5-mm upsloping
ST-segment elevation or depression), or nondiagnostic
(exercise-induced changes not interpretable).
Imaging by SPECT was performed following standard
protocols. No attenuation or scatter correction was used.
Image interpretation. Semiquantitative visual interpreta-
tion was performed using a 20-segment model, as previously
described (10). Each segment was scored using a 5-point
scoring system: 0  normal, 1  equivocal, 2  moderate,
3  severe reduction of radioisotope uptake, and 4 
apparent absence of detectable tracer uptake in a segment. A
summed stress score (SSS) was obtained by adding the
scores of the 20 segments of the stress images (20), and a
summed rest score (SRS) by adding the scores of the 20
segments on the rest images. To assess defect reversibility, a
summed difference score (SDS) was calculated by subtract-
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CAD  coronary artery disease
ECG  electrocardiogram/electrocardiographic
MPS  myocardial perfusion SPECT
PCI  percutaneous coronary intervention
SDS  summed difference score
SPECT  single-photon emission computed tomography
SRS  summed rest score
SSS  summed stress score
Tc-99m  technetium-99m
Figure 1. Flow chart of patients (pts).
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ing SRS from SSS, reflecting the severity and extent of
ischemia. An SSS 4 was considered normal, 4 to 8 mildly
abnormal, 9 to 13 moderately abnormal, and 13 severely
abnormal. For the degree of ischemia, an SDS of 0 was
considered nonischemic, 1 to 4 mildly ischemic, and 4
moderately to severely ischemic (13). Peri-infarction isch-
emia was defined as ischemia that was adjacent to an
infarcted area and was located in the same vessel territory.
Anteroseptal, lateral, and inferior/inferoseptal defects in
MPS were consistent with left anterior descending, left
circumflex, and right coronary artery restenosis, respectively.
Statistical analysis. A comparison between patient groups
was performed using the Student t test for continuous
variables and the Fisher exact test for categorical variables.
All continuous variables were described as the mean value
SD. A p value0.05 was considered statistically significant.
A logistic regression model was used to identify variables
that were associated with silent ischemia. Hypertension,
diabetes, number of risk factors, history of myocardial
infarction, history of revascularization, rate–pressure prod-
uct during stress testing, ischemia on the stress ECG, left
ventricular ejection fraction, and SDS were incorporated
into this model. Furthermore, receiver-operating character-
istic curves were used to identify an SDS that best separated
silent from symptomatic ischemia.
For prognostic purposes, a composite end point was
defined, including all-cause mortality, nonfatal myocardial
infarction, and “late” (not test-induced) revascularization. A
Cox proportional hazards model was used to evaluate
variables that were independently predictive of this compos-
ite end point. Age, hypertension, smoking, hypercholester-
olemia, diabetes, family history of CAD, number of dis-
eased vessels at the time of PCI, anginal status during stress
testing, maximal heart rate reached, ischemic ECG changes
during exercise testing, left ventricular ejection fraction, and
SDS were incorporated into the analysis. The incremental
value of nuclear testing was determined by calculating the
change in global chi-square after having added the nuclear
variables to the pre-scan information with respect to the
detection of silent ischemia (logistic regression model) and
with respect to prognosis (Cox model). The analyses were
done using the SPSS statistical package.
RESULTS
Of the 356 diagnostic patients (Fig. 1), 291 were male and
65 female, with an age range between 33 and 92 years
(average 64.7 10.1). A previous myocardial infarction was
reported in 56% and previous revascularization in 26% of
patients. At coronary angiography, 34% had single-vessel
disease and 66% had multivessel disease. Single “culprit”
vessel stenting was performed in 74% and multivessel
stenting in 26%. Usually, coronary stenoses with 70%
obstruction were not treated, leaving a patient population
for MPS testing at risk of both restenosis (ischemia in the
target vessel area) and progression of disease/ischemia in a
remote area with initially only mild stenoses.
Incidence of ischemia. Six months after PCI, 68 of tested
patients (19%) complained about angina, 45 (13%) had
ischemic stress-ECG changes (nondiagnostic ECG in 48
patients [13%]), and 113 (32%) had MPS evidence of
ischemia. Of note, only 43 (63%) of the 68 patients who
reported angina had MPS evidence of ischemia. Scinti-
graphic ischemia was located in the target vessel in 23% and
in remote areas in 9%. Thus, 81 patients had evidence of
target vessel ischemia, 32 had evidence of remote ischemia,
and 243 had no ischemia.
Target vessel ischemia and symptomatic status. In 81
patients with target vessel ischemia, angina was reported in
31 (38%), whereas ischemia was silent in 50 (62%). There-
fore, 14% of the overall diagnostic patient population (n 
356) had evidence of silent target vessel ischemia six months
after PCI and stenting. In Table 1, baseline characteristics
and stress test variables of patients with versus without
scintigraphic target vessel ischemia are compared; in addi-
tion, patients with ischemia are subclassified into those with
angina and those with silent ischemia.
Patients with evidence of ischemia differed from those
without ischemia in that they had more vessels dilated than
patients without ischemia, reached a lower heart rate during
stress testing, and more often had ischemic ECG changes.
Summed stress, rest, and difference scores were significantly
higher in patients with ischemia than in patients without
evidence of ischemia. Of note, anti-anginal drug withdrawal
was not different between the two groups.
When patients with silent versus symptomatic ischemia
were compared, patients with silent ischemia had less
cardiovascular risk factors, less frequently a history of
hypertension or previous cardiac surgery, and fewer vessels
with significant stenosis at the time of intervention than
patients with symptomatic ischemia (Table 1). Regarding
stress testing and nuclear variables, patients with silent
ischemia had less ischemic ECG changes and lower
summed stress and difference but not rest scores than
patients with symptomatic ischemia. Furthermore, patients
with silent ischemia more often had evidence of peri-
infarction ischemia. Of note, there was a tendency of
patients with silent ischemia to stop their anti-anginal drugs
more often before stress testing, as compared with their
symptomatic counterparts. However, the difference did not
reach statistical significance (p  0.08).
Of 31 patients with symptomatic ischemia after PCI,
81% presented with angina at baseline, whereas angina
occurred in 66% of 50 patients with silent ischemia after
PCI (p  0.15).
Predictors of silent ischemia and incremental value of
nuclear testing. Factors that influenced the occurrence of
silent ischemia were the number of risk factors, hyperten-
sion, history of CABG, number of vessels with significant
stenosis at the time of PCI, ischemic ECG changes, and,
with respect to nuclear variables, SSS and SDS (Table 1).
In the logistic regression model, a low SDS (extent and
severity of ischemia) turned out to be the only independent
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predictor of silent ischemia, indicating that patients with a
lower SDS were more likely to be asymptomatic, whereas
patients with a higher SDS were more likely to be symp-
tomatic. The odds ratio for the occurrence of silent ischemia
by SDS (decrease of SDS by 1) was 0.64 (95% confidence
interval 0.5 to 0.8; p  0.001). In addition, SDS added
significant incremental information to pre-scan information
with respect to the detection of silent ischemia, as deter-
mined by the increase of global chi-square (from 18 to 41;
p  0.001).
The receiver-operating characteristic curve revealed an
SDS of 4 to be the best separator of patients with silent
versus symptomatic ischemia (Fig. 2).
Outcome and predictors of prognosis. During the four-
year follow-up, 67 composite end points were reported in
the 307 patients (event rate of 22%, which is consistent with
Table 1. Baseline Patient Characteristics (n  324)
Ischemia*
(n  81)
No Ischemia*
(n  243) p Value
Symptomatic
Ischemia
(n  31)
Silent
Ischemia
(n  50) p Value
Baseline characteristics
Gender (% female) 17 19 NS 19 16 NS
Age (yrs) 64.7  9.6 64.7  10.2 NS 64.9  10.2 64.5  9.4 NS
No. of risk factors 2.2  1.2 2.1  1.0 NS 2.5  1.2 2.0  1.2 0.04
Hypertension (%) 49 44 NS 68 38 0.01
Smoking (%) 62 57 NS 71 58 NS
Hypercholesterolemia (%) 63 67 NS 71 58 NS
Diabetes (%) 15 14 NS 19 12 NS
Previous myocardial infarction (%) 53 57 NS 48 56 NS
Previous revascularizations (%) 26 26 NS 32 22 NS
PCI (%) 17 17 NS 16 18 NS
CABG (%) 10 10 NS 19 4 0.04
No. of vessels with stenosis 75% 2.0  0.7 1.9  0.8 NS 2.2  0.8 1.8  0.7 0.02
No. of dilated vessels at baseline 1.4  0.6 1.2  0.5 0.02 1.3  0.5 1.5  0.6 NS
Left ventricular ejection fraction (%) 61  10 61  14 NS 61  9 61  11 NS
Exercise and MPS variables
Antianginal drugs withdrawn (%) 67 60 NS 55 73 NS
Maximum heart rate (beats/min) 140  18 148  19 0.001 137  19 142  17 NS
Rate–pressure product† 25,369  5,538 25,472  7,699 NS 25,019  5,487 25,578  5,617 NS
Ischemic stress ECG (%) 31 5  0.001 48 20 0.01
SSS 9.2  5.9 2.6  4.9  0.001 11.5  5.6 7.7  5.7 0.005
SRS 5.2  4.4 2.6  4.9  0.001 5.5  4.4 5.0  4.4 NS
SDS 4.0  3.0 0  0.001 5.9  3.0 2.8  2.4  0.001
Peri-infarction ischemia (%) 27 — — 13 36 0.02
*In target vessel. †Heart rate  blood pressure at peak exercise. Data are presented as the percentage of patients or mean value  SD.
CABG  coronary artery bypass grafting; ECG  electrocardiogram; MPS  myocardial perfusion SPECT; NS  not significant; PCI  percutaneous coronary
intervention; SDS  summed difference score; SRS  summed rest score; SSS  summed stress score.
Figure 2. Receiver-operating characteristic curve for the discrimination between silent and symptomatic ischemia. Note that the best discrimination of silent
versus symptomatic ischemia was found with a summed difference score (SDS) of 4.
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a 5% overall event rate per year) (Table 2): 16 deaths, 8
nonfatal myocardial infarctions, and 50 late revasculariza-
tions (36 PCI, 14 CABG). End points were observed more
frequently in patients with evidence of ischemia than in
patients without ischemia (p  0.001) (Table 2). This
difference was mostly driven by more frequent revascular-
ization procedures in the former (p  0.001).
Among all possible prognostic factors tested, the Cox
model identified a history of hypertension to be a borderline
predictor and diabetes mellitus as well as extent of ischemia
(SDS) to be independent predictors of the composite end
point (Table 3). Among these, SDS was the most powerful
predictor of events. This resulted in significantly different
event-free survival curves for patients with no (SDS  0),
mild (SDS  1 to 3), and moderate/severe ischemia (SDS
 4), with 17%, 29%, and 69% event rates (annual event
rates of 4%, 7%, and 17%), respectively (Fig. 3). Event-free
survival curves for patients without ischemia, with silent
ischemia, and symptomatic ischemia (Fig. 4) paralleled the
event-free survival curves in Figure 3, with 17%, 32%, and
52% (annual event rates of 4%, 8%, and 13%), respectively.
Patients with silent ischemia tended to have better event-
free survival than patients with symptomatic ischemia (p 
0.12). However, patients with silent and symptomatic isch-
emia had a worse prognosis than patients without evidence
of ischemia (p  0.006 and p  0.0001, respectively). If
patients without ischemia were subclassified into those with
(n  25) and those without symptoms (n  217), then the
former group had an event-free survival that was signifi-
cantly worse than that of the latter group (p  0.01) and
very similar to that of patients with silent ischemia (data not
shown).
Prognostic information contained in clinical, ECG, and
scintigraphic findings are compared in Figure 5. It shows
the incremental prognostic information (significant increase
in global chi-square) after adding ECG variables to clinical
findings and, in a second step, after adding nuclear infor-
mation (SDS) to all pre-scan information (Fig. 5).
Seventeen patients had been excluded from this prognos-
tic evaluation because of MPS-induced early revasculariza-
tion. Eleven of them (65%) were symptomatic and 41% had
significant ST-segment depression during the test. In addi-
tion, SDS was somewhat higher than in the other patients
with target vessel ischemia (4.9  3.2 vs. 3.7  3.0; p 
NS). During follow-up, one of these patients died (after 3
years), one had CABG (after 4.5 years), and three had PCI
(one in the target vessel, two in other coronary vessels, which
is consistent with an event rate of 29%, or 7% per year).
In 32 patients without target vessel ischemia but evidence
of ischemia in another coronary vessel territory, 19 (59%)
had silent ischemia and 8 (25%) had ischemic ECG
changes. During follow-up in these patients, one patient
died and eight needed revascularization procedures (2
CABG, 6 PCI), which is consistent with an event rate of
28%, or an annual event rate of 7%.
DISCUSSION
The present analysis of a large patient population prospec-
tively tested six months after PCI and stenting revealed
important findings regarding the incidence and long-term
outcome of patients with silent versus symptomatic ischemia
after PCI and stenting. Twenty three percent of patients
developed recurrent ischemia in the target vessel, as shown by
MPS. In patients with target vessel ischemia, angina was
present in only 38% and ischemic ECG changes in 31%. The
extent and severity of ischemia, as described by SDS, was the
only independent predictor of silent ischemia. In addition,
MPS allowed us to differentiate between ischemia related to
restenosis (target vessel area) and that related to progression of
disease in remote areas. Nuclear testing added incremental
value to clinical and ECG findings to detect silent ischemia.
Patients with silent ischemia had a smaller extent of ischemia
than patients with symptomatic ischemia.
Among several prognostic factors tested, the severity and
extent of ischemia (SDS) was the most powerful predictor
of outcome. Patients without evidence of ischemia, with a
small, moderate, or large extent of ischemia after six
months, had long-term annual event rates of 4%, 7%, and
Table 3. Independent Predictors of Composite End Point*
Relative Risk 95% Confidence Interval p Value
Hypertension 1.73 0.99–3.0 0.056
Diabetes 1.98 1.07–3.68 0.03
SDS 1.2 1.09–1.34  0.001
*Death, nonfatal myocardial infarction, and late revascularization.
SDS  summed difference score (extent of ischemia).
Table 2. Outcome Events (n  307)
Ischemia
(n  65)
No Ischemia
(n  242) p Value
Symptomatic
Ischemia
(n  21)
Silent
Ischemia
(n  44) p Value
Composite end point* (%) 38 17 0.001 52 32 NS
All-cause mortality (%) 6 5 NS 10 5 NS
Nonfatal myocardial
infarction
2 3 NS 0 2 NS
Revascularization 32 12  0.001 43 27 NS
PCI 20 10 0.03 24 18 NS
CABG 12 2 0.003 19 9 NS
*Death, nonfatal myocardial infarction, and late revascularization.
Abbreviations as in Table 1.
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17%, respectively. In addition, the information contained in
the SDS added significant incremental prognostic informa-
tion to the evaluation of patients after PCI and stenting.
Survival curves paralleled those of no, silent, and symptom-
atic ischemia, indicating that silent ischemia, associated
with less severe ischemia, carries a certain distinct risk which
lies in the middle between no and symptomatic ischemia.
Incidence of silent ischemia and restenosis after PCI. In
a pooled analysis (n  3,774) of angiographic data by
Ruygrok et al. (21), a restenosis rate of 23% was found after
PCI and PCI and stenting. Of these patients, 55% had
silent restenosis. This finding is in accordance with the
present analysis and a previously published report from our
group of patients with PTCA only (6). In contrast to that
study, where an overall ischemia rate of 28% was found six
months after balloon angioplasty (no stents) in a group of
490 consecutive patients, the incidence of target vessel
ischemia was now 23% with stents, most likely reflecting the
Figure 3. Kaplan-Meier event-free survival curves by summed difference score (SDS) categories. Patients with an SDS of 0 (n 242) had significantly lower
event rates than patients with an SDS of 1 to 4 (n  49; p  0.03); these patients had significantly lower event rates than patients with SDS 4 (n 
16; p  0.005). Note the significant differences in outcome between patients with no, mild, and moderate to severe ischemia, as defined by SDS. MPS 
myocardial perfusion SPECT.
Figure 4. Kaplan-Meier event-free survival curves by symptomatic status. Patients without ischemia (n  242) had significantly lower event rates than
patients with silent (n  44) or symptomatic ischemia (n  21; p  0.006 and p  0.0001, respectively); patients with silent ischemia tended to have lower
event rates than patients with symptomatic ischemia (p  0.12). MPS  myocardial perfusion SPECT.
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reduction of restenosis by stents. This finding has been
extended by the present analysis, which determined SDS to
be the only independent predictor of silent ischemia. In the
study by Ruygrok et al. (21), only male gender, the reference
vessel diameter at follow-up, and a lesser lesion severity after
six months were associated with asymptomatic restenosis.
Chest pain during an exercise stress test has been shown
to be a poor marker of restenosis, with reported sensitivities
of only 24% to 63% (22,23). Electrocardiographic changes
are not very accurate for detecting restenosis, too, with
reported sensitivities ranging from 15% to 79% (mean 56%)
and specificities from 33% to 88% (mean 73%) (6,22–26). In
contrast, a number of reports have indicated that nuclear
imaging is more accurate for restenosis detection, with a
sensitivity of 87% and a specificity of 78% in a pooled
analysis (26).
Outcome and prognostic predictors. Routine six-month
follow-up angiography, followed by high rates of repeat
intervention of restenotic lesions, could be related to re-
duced 10-year mortality rates (27,28). This was indepen-
dent of whether restenosis was symptomatic or silent. In
addition, Pancholy et al. (29) showed that the extent of
perfusion abnormality and a history of diabetes mellitus
were the most important predictors of events in patients
with chronic CAD and that silent ischemia had similar
prognostic power as compared with symptomatic ischemia
(30–32). These prognostic observations are in accordance
with the findings of the present analysis, which demon-
strated that the extent of ischemia (SDS) and diabetes were
independent predictors of events during long-term
follow-up after PCI and stenting.
In addition, the present analysis suggests that the extent
of ischemia, as defined by SDS, is well suited for risk
stratification: patients with a large ischemic region and/or
symptomatic ischemia have the highest rate of subsequent
events, whereas a smaller ischemic area, as found in silent
ischemia, was associated with a lower event rate. Impor-
tantly, however, the event rate of silent ischemia was
significantly higher than that of patients without ischemia,
although somewhat lower than that of patients with symp-
tomatic ischemia.
Patients with early (six-month) induced revascularization
tended to have a higher SDS than the other patients with
evidence of target vessel ischemia, but after repeat interven-
tion, they had a favorable long-term outcome (although the
number is too small to draw definitive conclusions). In
contrast, patients with remote ischemia indicating progres-
sion of CAD had similar event rates as patients with target
vessel ischemia. Thus, nuclear testing had significant incre-
mental value for risk prediction, in addition to clinical and
ECG parameters.
Study limitations. No systematic follow-up angiography
was performed in this clinical study; therefore, the accuracy
of MPS to detect angiographic restenosis cannot be de-
scribed. However, this was done previously (26) and was not
the aim of the present study. Death and myocardial infarc-
tion rates were low, as could be expected for such a patient
population; therefore, event rates were mainly driven by late
revascularizations. To exclude revascularizations indicated
by the index MPS in this study, all patients who had
revascularization within 60 days of this test were excluded.
Still, the prognostic power of the test described relates
mainly to nonfatal events and not to mortality. Of note,
patients who died tended to have a higher SSS and SRS
than patients with late revascularization (SSS 7.7  10.5 vs.
5.2  7.4, p  0.28 and SRS 6.2  9.6 vs. 3.1  4.6, p 
0.09), reflecting the impact of a higher SRS as a surrogate
marker of left ventricular ejection fraction as a major
predictor of survival.
Conclusions. Based on these observations, 23% of patients
had target vessel ischemia six months after PCI and stent-
ing, which was silent in 62%, representing 14% of the total
patient population. Patients with silent ischemia had a
smaller extent of ischemia than did symptomatic patients.
However, the prognosis of patients with silent ischemia
Figure 5. Incremental value of nuclear testing in the evaluation of long-term prognosis. *#Significant increase in global chi-square (*p 0.001, #p 0.002).
ECG  electrocardiogram; SDS  summed difference score.
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tended to be better than that of patients with angina but was
distinctively worse than that of patients without ischemia.
The extent of ischemia, as represented by SDS, added
incremental information to clinical and ECG variables with
respect to the detection of silent ischemia and with respect
to prognosis. The modality of MPS allowed separation into
low, medium, and high risk for adverse events and is
therefore suitable for risk stratification several months after
PCI and stenting.
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